Evidence map›Paper›PMID 41361356›Full record

ArticleScientific reports2025

Management status of patients with chronic kidney disease across medical specialties in Japan: a real-world data analysis.

Shoichi Maruyama, Tetsuhiro Tanaka, Hirobumi Igawa, Mitsuru Hoshino, Shoichiro Inokuchi, Shuji Kaneko, Hirokazu Takaya, Asuka Ozaki

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tetsuhiro TanakaDepartment of Nephrology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hirobumi IgawaCardiovascular, Renal and Metabolism, BioPharmaceuticals Medical, AstraZeneca, Osaka, Japan.
Mitsuru HoshinoEvidence & Observational Research, Medical, AstraZeneca, Osaka, Japan.
Shoichiro InokuchiReal World Evidence Division, Pharmaceutical Division, JMDC Inc., Tokyo, Japan.
Shuji KanekoReal World Evidence Division, Pharmaceutical Division, JMDC Inc., Tokyo, Japan.
Hirokazu TakayaReal World Evidence Division, Pharmaceutical Division, JMDC Inc., Tokyo, Japan.
Asuka OzakiCardiovascular, Renal and Metabolism, BioPharmaceuticals Medical, AstraZeneca, Osaka, Japan. asuka.ozaki@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) contributes to poor renal and cardiovascular outcomes, necessitating early detection and intervention. The current study investigated the variability in CKD management practices across clinical specialties in Japan. Real-world electronic health records of 788,059 patients with suspected CKD between January 2004 and September 2021 were analyzed. Only 1.2% of patients received care in a nephrology department. However, nephrology involvement significantly increased the proportion of patients undergoing quantitative urine protein assessments and receiving a CKD diagnosis. This trend was evident in cardiology, urology, rheumatology, and endocrinology/metabolism departments, where nephrology involvement resulted in more frequent testing and earlier CKD diagnosis. Despite these benefits, the overall proportion of patients with nephrology involvement remains low, especially in the early stages of CKD. These findings highlight the considerable variability in CKD diagnosis and management approaches across clinical departments. Because quantitative urine protein assessment is critical for precise CKD diagnosis and patient care, strategies such as promoting interdepartmental collaboration with nephrology departments and establishing standardized diagnostic protocols tailored to individual specialties and facilities should be prioritized. Implementing such facility- and specialty-specific measures is crucial for enhancing early CKD detection and intervention, ultimately improving clinical outcomes in patients at risk of CKD progression.

Indexed as

Renal Insufficiency, ChronicAgedData AnalysisDisease ManagementElectronic Health RecordsFemaleHumansJapanMaleMiddle AgedProteinuria

Identifiers

PMID41361356
PMCPMC12796421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.